Last reviewed · How we verify
Deacetoxycefotaxime (CEFETAMET)
Deacetoxycefotaxime (generic name: CEFETAMET) is a cefetamet drug. It is currently in Phase 2 development.
Deacetoxycefotaxime works by inhibiting the bacterial enzyme responsible for cell wall synthesis, ultimately leading to cell lysis and death.
Deacetoxycefotaxime, also known as CEFETAMET, is a third-generation cephalosporin antibiotic belonging to the cefetamet drug class. It is a small molecule modality, but its current commercial status and approved indications are unknown. The pharmacokinetic properties of CEFETAMET include a half-life of 2.1 hours and bioavailability of 47%. As a cephalosporin antibiotic, it works by inhibiting bacterial cell wall synthesis, but its specific target is unknown. Further research is needed to determine its clinical utility and safety profile.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CEFETAMET |
|---|---|
| Drug class | cefetamet |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells are like buildings with walls. Bacteria have special machines that build these walls, and deacetoxycefotaxime blocks these machines, causing the walls to collapse and the bacteria to die.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Deacetoxycefotaxime CI brief — competitive landscape report
- Deacetoxycefotaxime updates RSS · CI watch RSS
Frequently asked questions about Deacetoxycefotaxime
What is Deacetoxycefotaxime?
How does Deacetoxycefotaxime work?
What is the generic name of Deacetoxycefotaxime?
What drug class is Deacetoxycefotaxime in?
What development phase is Deacetoxycefotaxime in?
Related
- Drug class: All cefetamet drugs
- Therapeutic area: All drugs in Infectious Disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing